• toxicity
  • The purpose of this study is to determine the plasma concentration and exposure time required for cyclophosphamide to produce optimal immunosuppressive activity with minimal toxicity in participants with severe systemic sclerosis. (clinicaltrials.gov)
  • urine
  • Jardine I, Fenselau C, Appler M, Kan MN, Brundrett RB, Colvin M (1978) Quantitation by gas chromatography-chemical ionisation mass spectrometry of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard in plasma and urine of patients receiving cyclophosphamide therapy. (springer.com)
  • exposure
  • First trimester exposure to cyclophosphamide for the treatment of cancer or lupus displays a pattern of anomalies labeled "cyclophosphamide embryopathy," including growth restriction , ear and facial abnormalities, absence of digits and hypoplastic limbs. (wikipedia.org)
  • Disease
  • Cyclophosphamide is also used to treat minimal change disease , severe rheumatoid arthritis , granulomatosis with polyangiitis and multiple sclerosis . (wikipedia.org)
  • In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, cyclophosphamide may induce a remission. (nih.gov)
  • Case presentation: Pres in the setting of goodpasture disease treated with cyclophosphamide. (springer.com)
  • therapy
  • Recommended first line therapy often includes: cyclophosphamide alternating with a corticosteroid. (wikipedia.org)
  • Chlorambucil Cyclosporine Tacrolimus Cyclophosphamide Mycophenolate mofetil Rituximab Perhaps the most difficult aspect of membranous glomerulonephritis is deciding which people to treat with immunosuppressive therapy as opposed to simple "background" or anti-proteinuric therapies. (wikipedia.org)